# Kailera Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kailera-therapeutics

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.kailera.com/
- Total disclosed funding: $800M
- Latest round: Series B (Oct 14, 2025)
- Investors on record: 14

## About

Founded in 2024 and based in Massachusetts, US, Kailera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. In October 2024, Kailera Therapeutics raised USD 400 million in Series A funding co-led by Atlas Venture, Bain Capital, RTW Investments, and Lyra Capital. As of 2024, the company is led by its CEO, Ron Renaud. In October 2025, Kailera Therapeutics, Inc. raised USD 600 million in series B funding led by Bain Capital, with participation from Adage Capital Management, Atlas Venture, RTW Investments, Sirona Capital, CPP Investment Board, Invus, Janus Henderson Investors, Perseverance Capital, Qatar Investment Authority, Royalty Pharma, Surveyor Capital, and T Rowe Price.

Kailera Therapeutics focuses on developing treatments for obesity and weight-related conditions. The company’s pipeline includes a diverse range of therapies like KAI-9531, a dual GLP-1/GIP receptor agonist investigated for obesity and type 2 diabetes; KAI-7535, an oral GLP-1 receptor agonist targeting obesity and type 2 diabetes; and KAI-4729, a tri-agonist targeting GLP-1, GIP, and glucagon receptors for the treatment of obesity and type 2 diabetes. These therapies leverage various mechanisms of action, including GLP-1/GIP receptor dual agonists, GLP-1 receptor agonists, and GLP-1/GIP/Glucagon receptor tri-agonists.

The company plans to utilize the October 2025 funding to hire more staff, develop obesity treatments, and run clinical trials.

## Funding rounds

- Series B, Oct 14, 2025, $500M — Atlas Venture, Bain Capital, T Rowe Price, CPP Investment Board, Adage Capital Management, Janus Henderson Investors, Royalty Pharma, Surveyor Capital, Invus Financial Advisors, RTW Investments, Perseverance Capital, Sirona Capital, Qatar Investment Authority
- Series A, Oct 1, 2024, $300M — Atlas Venture, Bain Capital, RTW Investments, Lyra Capital

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B
- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series A, Series B
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series A, Series B
- Lyra Capital — Series A
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series B
- CPP Investment Board — Series B
- Adage Capital Management — Series B
- Janus Henderson Investors — Series B
- Royalty Pharma (https://capitalatlas.ai/funds/royalty-pharma) — Series B
- Surveyor Capital — Series B
- Invus Financial Advisors (https://capitalatlas.ai/funds/invus-financial-advisors) — Series B
- Perseverance Capital (https://capitalatlas.ai/funds/perseverance-capital) — Series B
- Sirona Capital (https://capitalatlas.ai/funds/sirona-capital) — Series B
- Qatar Investment Authority (https://capitalatlas.ai/funds/qatar-investment-authority) — Series B